TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Proteomics International Laboratories Ltd. ( (AU:PIQ) ) is now available.
Proteomics International Laboratories Ltd has announced the presentation of its PromarkerEso diagnostic test results at the World Congress for Esophageal Diseases. The test, which detects early stages of esophageal adenocarcinoma with high accuracy, is now available across Australia through telehealth consultations and physician referrals. This development could significantly improve health outcomes by enabling earlier diagnosis and treatment of esophageal cancer, a condition often diagnosed too late for effective intervention.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a pioneer in precision diagnostics, focusing on developing innovative diagnostic tests to improve health outcomes. The company is known for its first-in-class blood tests, such as PromarkerEso, which targets early detection of diseases like esophageal adenocarcinoma.
Average Trading Volume: 370,276
Technical Sentiment Signal: Sell
Current Market Cap: A$47.47M
See more insights into PIQ stock on TipRanks’ Stock Analysis page.